MARIZOMIB: A POTENT IV PROTEASOME INHIBITOR

Marizomib is a novel, brain-penetrant proteasome inhibitor, which inhibits all three proteasome subunits. Triphase developed clinical proof of concept for marizomib in glioma resulting in Celgene (now part of Bristol-Myers Squibb) acquiring the assets related to marizomib from Triphase in November 2016.